文献速递淋巴瘤

Wnt5a通过ROR1依赖的NF-κB激活增强慢性淋巴细胞白血病中MMP-9表达与侵袭性

Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2025-04-28

研究发现高表达ROR1的循环慢性淋巴细胞白血病(CLL)细胞MMP-9水平显著更高;Wnt5a刺激可增强MMP-9表达与释放并提高CLL细胞侵袭Matrigel的能力,该效应不被BTK抑制剂伊布替尼或泽布替尼抑制,但可被抗ROR1单抗zilovertamab阻断;siRNA沉默NF-κB-p65或使用NF-κB抑制剂可阻断Wnt5a诱导的MMP-9及侵袭能力。

要点

  • 高表达ROR1的循环CLL细胞MMP-9水平显著更高。
  • Wnt5a刺激增强CLL细胞MMP-9表达与释放并提高侵袭Matrigel能力。
  • 该效应不被伊布替尼或泽布替尼抑制,但可被抗ROR1单抗zilovertamab阻断。

核心结论

  • 作者结论认为Wnt5a诱导的ROR1信号可通过激活NF-κB诱导CLL细胞表达MMP-9,从而增强CLL细胞转运所需的血管外渗和淋巴组织浸润。

研究设计与样本

  • 研究为体外实验,检测循环CLL细胞中ROR1与MMP-9表达,并用Wnt5a刺激、BTK抑制剂、抗ROR1单抗、siRNA及NF-κB和MMP-9抑制剂进行干预。

主要发现

  • 高表达ROR1的循环CLL细胞MMP-9水平显著更高。
  • Wnt5a刺激可增强MMP-9表达与释放至培养基并提高CLL细胞在Boyden小室实验中侵袭Matrigel的能力。
  • Wnt5a上述效应不被伊布替尼或泽布替尼抑制,但可被抗ROR1人源化单抗zilovertamab阻断。
  • siRNA沉默NF-κB-p65或使用NF-κB抑制剂(CAS 545380-34-5)可阻断Wnt5a诱导MMP-9及增强侵袭能力的作用。
  • siRNA沉默MMP9或使用MMP-9抑制剂(CAS 1177749-58-4)也可阻断Wnt5a诱导的CLL细胞侵袭能力。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Matrix metalloproteinase-9 (MMP-9) facilitates the extravasation and lymphoid-tissue infiltration of chronic lymphocytic leukemia (CLL) cells. Prior studies found that high level expression of MMP-9 in CLL associates more aggressive disease. We find that circulating CLL cells that express high levels the onco-embryonic protein ROR1 express significantly higher levels of MMP-9. Stimulation of CLL cells with Wnt5a could enhance expression and the release of MMP-9 into the culture media and increase the capacity of CLL cells to invade Matrigel in a Boyden-Chamber Assay. Such effects of Wnt5a could not be inhibited by BTK inhibitors such as ibrutinib or zanubrutinib, but could be blocked by zilovertamab, a humanized mAb specific for ROR1. We found that siRNA silencing of NF-κB-p65 or use of an NF-κB inhibitor (CAS 545380-34-5) blocked the capacity of Wnt5a to induce MMP-9 or enhance the invasive capacity of treated CLL cells. Moreover, siRNA directed silencing of MMP9 or treatment with an MMP-9 inhibitor (CAS 1177749-58-4) also blocked the invasive capability of CLL cells induced by Wnt5a. We conclude that Wnt5a-induced ROR1-signaling can induce expression of MMP-9 on CLL cells through activation of NF-κB, thereby enhancing the extravasation and lymphoid-tissue infiltration required for CLL cell trafficking.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hasan MK, Widhopf Ii GF, Ghia EM, et al. Wnt5a induces ROR1 dependent NF-κB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia. Leukemia. 2025. PMID: 40295829. doi:10.1038/s41375-025-02616-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。